Antiobesity Market Global Report 2026

The antiobesity market size has grown strongly in recent years. It will grow from $4.13 billion in 2025 to $4.53 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to increasing global obesity rates, limited effectiveness of lifestyle-only interventions, availability of appetite suppressants, rising burden of metabolic disorders, physician-led weight management.

The antiobesity market size is expected to see strong growth in the next few years. It will grow to $6.61 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to the increasing prevalence of diabetes and obesity, advancements in hormone-based drugs, expansion of reimbursement coverage, growing obesity awareness, and increasing demand for sustainable weight loss solutions. Major trends in the forecast period include the rapid adoption of GLP-1-based therapies, growing preference for prescription weight loss drugs, increasing use of combination anti-obesity therapies, greater focus on long-term weight management, and expanding access to obesity treatment.

The increasing prevalence of obesity is expected to drive the growth of the anti-obesity drugs market going forward. Obesity is a chronic metabolic condition characterized by excessive accumulation of body fat, which increases the risk of serious health complications, including diabetes, cardiovascular diseases, osteoarthritis, and certain cancers. The increasing prevalence of obesity is attributed to the growing consumption of ultra-processed foods that are high in sugars, unhealthy fats, and refined carbohydrates, along with sedentary lifestyles that limit physical activity. This rise in obesity prevalence is increasing the demand for effective anti-obesity medical interventions, supportive weight management therapies, and long-term treatment solutions to reduce associated health risks and enhance patient outcomes. For instance, in March 2024, according to the World Obesity Federation, a UK-based organization focused on obesity research and advocacy, 79% of adults with overweight and obesity and 88% of children with overweight and obesity are projected to be living in low- and middle-income countries by 2035. Therefore, the increasing prevalence of obesity is driving the growth of the anti-obesity drugs market.

Major companies operating in the antiobesity market are emphasizing product innovation and formulation, including dual glucose-dependent insulinotropic peptide receptor agonists, to deliver more effective weight loss, enhanced metabolic outcomes, and improved tolerability. These therapies utilize synergistic effects on appetite suppression, insulin sensitivity, and energy expenditure to achieve greater efficacy compared with earlier-generation GLP-1-only treatments. For instance, in December 2024, Eli Lilly, a US-based pharmaceutical company, received FDA approval for Zepbound (tirzepatide), making it the first and only prescription dual GIP/GLP-1 agonist approved for chronic weight management. Tirzepatide has demonstrated strong weight-loss efficacy, with participants in phase 3 trials achieving substantial reductions in body weight. With this new indication, Zepbound is expected to strengthen Lilly’s leadership in the precision obesity therapy space, addressing the growing demand for long-acting, high-efficacy treatments.

In August 2023, Eli Lilly, a US-based pharmaceutical company, acquired Versanis Bio for an undisclosed amount. Through this acquisition, Eli Lilly aims to strengthen its antiobesity drug portfolio by incorporating Versanis Bio’s innovative therapies targeting metabolic and weight-management pathways, supporting the development of next-generation treatments for obesity and related metabolic disorders. Versanis Bio is a US-based biotechnology company that specializes in developing novel therapeutics for obesity and metabolic diseases, with a strong track record in preclinical and early-stage clinical research.

Major companies operating in the antiobesity market are Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen Inc., Rhythm Pharmaceuticals Inc., Zydus Cadila, Norgine B.V., Vivus Inc., Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., Eli Lilly and Company, Amgen Inc., AstraZeneca PLC, Viking Therapeutics Inc., Structure Therapeutics Inc., Gelesis Inc., Sanofi S.A., F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd.

North America was the largest region in the anti-obesity market in 2025. Middle East is expected to be the fastest-growing region in the antiobesity market. The regions covered in the antiobesity market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antiobesity market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 1-3 business days.